$ZVRA
ZEVRA THERAPEUTICS, INC.

2015 Q3 Form 10-Q Financial Statement

#000156459015007410 Filed on August 14, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.150M $3.190M $1.330M
YoY Change 97.25% 139.85%
% of Gross Profit
Research & Development $4.328M $2.768M $1.715M
YoY Change 33.05% 61.4%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K $20.00K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $6.480M $5.956M $3.045M
YoY Change 49.34% 95.6%
Operating Profit -$6.480M -$5.956M -$3.045M
YoY Change 49.34% 95.6%
Interest Expense $687.0K $654.0K $704.0K
YoY Change 297.11% -7.1%
% of Operating Profit
Other Income/Expense, Net -$3.244M -$23.79M -$533.0K
YoY Change 14.39% 4362.85%
Pretax Income -$9.724M -$29.74M -$3.578M
YoY Change 35.53% 731.27%
Income Tax $20.00K -$6.000K
% Of Pretax Income
Net Earnings -$9.744M -$29.74M -$3.572M
YoY Change 36.53% 732.67%
Net Earnings / Revenue
Basic Earnings Per Share -$0.68 -$2.45
Diluted Earnings Per Share -$0.68 -$2.45 -$23.80M
COMMON SHARES
Basic Shares Outstanding 14.23M 12.16M
Diluted Shares Outstanding 12.16M

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.00M $64.20M
YoY Change 210.53%
Cash & Equivalents $59.01M $64.22M $22.96M
Short-Term Investments
Other Short-Term Assets $600.0K $600.0K
YoY Change 500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $59.60M $64.83M
YoY Change 212.04%
LONG-TERM ASSETS
Property, Plant & Equipment $400.0K $352.0K
YoY Change 33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.400M $56.00K
YoY Change -33.33%
Total Long-Term Assets $1.800M $1.709M
YoY Change -25.0%
TOTAL ASSETS
Total Short-Term Assets $59.60M $64.83M
Total Long-Term Assets $1.800M $1.709M
Total Assets $61.40M $66.54M
YoY Change 185.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.000M $4.900M
YoY Change 14.29%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.800M $0.00
YoY Change
Total Short-Term Liabilities $6.792M $4.910M
YoY Change 88.67%
LONG-TERM LIABILITIES
Long-Term Debt $19.30M $18.90M
YoY Change 9.04%
Other Long-Term Liabilities $41.10M $39.30M
YoY Change 223.62%
Total Long-Term Liabilities $60.40M $58.20M
YoY Change 98.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.792M $4.910M
Total Long-Term Liabilities $60.40M $58.20M
Total Liabilities $67.16M $63.08M
YoY Change 97.54%
SHAREHOLDERS EQUITY
Retained Earnings -$95.62M -$85.88M
YoY Change
Common Stock $89.88M $89.34M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.746M $3.463M
YoY Change
Total Liabilities & Shareholders Equity $61.42M $66.54M
YoY Change 185.66%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$9.744M -$29.74M -$3.572M
YoY Change 36.53% 732.67%
Depreciation, Depletion And Amortization $20.00K $20.00K $20.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$4.620M -$5.250M -$2.930M
YoY Change 18.77% 79.18%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K -$20.00K -$10.00K
YoY Change 500.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$60.00K -$20.00K -$10.00K
YoY Change 100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -550.0K 59.23M 24.84M
YoY Change 1275.0% 138.45%
NET CHANGE
Cash From Operating Activities -4.620M -5.250M -2.930M
Cash From Investing Activities -60.00K -20.00K -10.00K
Cash From Financing Activities -550.0K 59.23M 24.84M
Net Change In Cash -5.230M 53.96M 21.90M
YoY Change 33.08% 146.39%
FREE CASH FLOW
Cash From Operating Activities -$4.620M -$5.250M -$2.930M
Capital Expenditures -$60.00K -$20.00K -$10.00K
Free Cash Flow -$4.560M -$5.230M -$2.920M
YoY Change 17.53% 79.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Assets
Assets
13714000
CY2015Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4878000
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3903000
CY2014Q4 us-gaap Liabilities
Liabilities
38015000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Assets
Assets
66539000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1616000
CY2015Q2 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
11326000
CY2014Q4 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
10853000
CY2015Q2 kmph Derivative And Warrant Liability Noncurrent
DerivativeAndWarrantLiabilityNoncurrent
39279000
CY2014Q4 kmph Derivative And Warrant Liability Noncurrent
DerivativeAndWarrantLiabilityNoncurrent
15966000
CY2015Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
11000
CY2014Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
26000
CY2015Q2 us-gaap Liabilities
Liabilities
63076000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
24207000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
89337000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1650000
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85877000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50160000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
3463000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-48508000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66539000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13714000
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
140000000
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14228401
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2381041
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14228401
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2381041
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q2 us-gaap Assets Current
AssetsCurrent
64830000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2014Q4 us-gaap Assets Current
AssetsCurrent
10278000
CY2015Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1301000
CY2014Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1468000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
352000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
352000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56000
CY2015Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
32000
CY2014Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
32000
CY2014Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
7235000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Trading Symbol
TradingSymbol
KMPH
dei Entity Registrant Name
EntityRegistrantName
KEMPHARM, INC
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4910000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3935000
CY2015Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
7550000
dei Entity Central Index Key
EntityCentralIndexKey
0001434647
dei Document Type
DocumentType
10-Q
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14228401
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64223000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10255000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
607000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23000
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
0
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
0
us-gaap Sales Revenue Net
SalesRevenueNet
0
us-gaap Sales Revenue Net
SalesRevenueNet
0
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2768000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1715000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4887000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2752000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3188000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1330000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4165000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1864000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
5956000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
3045000
us-gaap Operating Expenses
OperatingExpenses
9052000
us-gaap Operating Expenses
OperatingExpenses
4616000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5956000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3045000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9052000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4616000
CY2014Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1900000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1900000
CY2015Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
477000
CY2014Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
159000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
954000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
159000
CY2015Q2 us-gaap Interest Expense
InterestExpense
649000
CY2014Q2 us-gaap Interest Expense
InterestExpense
704000
us-gaap Interest Expense
InterestExpense
1280000
us-gaap Interest Expense
InterestExpense
800000
CY2015Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
22661000
CY2014Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1570000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
24423000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1812000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23787000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-533000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26657000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-871000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29743000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3578000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35709000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5487000
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-29743000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-3572000
us-gaap Net Income Loss
NetIncomeLoss
-35716000
us-gaap Net Income Loss
NetIncomeLoss
-5476000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.45
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.50
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.91
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.30
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12157514
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2381041
us-gaap Share Based Compensation
ShareBasedCompensation
964000
us-gaap Share Based Compensation
ShareBasedCompensation
117000
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2381041
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7272326
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
40000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
38000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-976000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2175000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
589000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9254000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3822000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-40000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-11000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
59892000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
668000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
25000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
163000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
15000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
16000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
63262000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
24819000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
53968000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
20986000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1969000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22955000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
28209000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
1870000
kmph Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
1110000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
4160000
kmph Issuance Of Warrant Allocated To Debt Discount
IssuanceOfWarrantAllocatedToDebtDiscount
7610000
kmph Embedded Put Option Allocated To Debt Discount
EmbeddedPutOptionAllocatedToDebtDiscount
220000
kmph Issuance Of Preferred For Transaction Fee
IssuanceOfPreferredForTransactionFee
1500000
kmph Deferred Offering Costs Included In Accounts Payable And Accrued Expense
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense
313000
us-gaap Interest Paid
InterestPaid
1000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, the fair value of the Company&#8217;s common stock prior to the IPO and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</p></div>
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7.5 reverse stock split
CY2015Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.13
CY2015Q2 us-gaap Line Of Credit
LineOfCredit
50000
CY2014Q2 us-gaap Line Of Credit
LineOfCredit
50000
CY2015Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2015Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2015Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2014Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
41737048
kmph Temporary Equity Shares Issuance
TemporaryEquitySharesIssuance
3200000
kmph Class Of Warrants Or Right Exercise
ClassOfWarrantsOrRightExercise
3205
kmph Conversion Of Preferred Stock To Common Stock Upon Initial Public Offering Shares
ConversionOfPreferredStockToCommonStockUponInitialPublicOfferingShares
44940253
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
kmph Common Stock Warrants Exercised
CommonStockWarrantsExercised
12251
CY2015Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7347857
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10796686
kmph Common Stock Warrants Exercised
CommonStockWarrantsExercised
0
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
666666
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
800000
CY2015Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2014Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
873000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
92000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
964000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
117000
CY2015Q2 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
39279000
CY2014Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
15966000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5490359
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10995062

Files In Submission

Name View Source Status
0001564590-15-007410-index-headers.html Edgar Link pending
0001564590-15-007410-index.html Edgar Link pending
0001564590-15-007410.txt Edgar Link pending
0001564590-15-007410-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kmph-10q_20150630.htm Edgar Link pending
kmph-20150630.xml Edgar Link completed
kmph-20150630.xsd Edgar Link pending
kmph-20150630_cal.xml Edgar Link unprocessable
kmph-20150630_def.xml Edgar Link unprocessable
kmph-20150630_lab.xml Edgar Link unprocessable
kmph-20150630_pre.xml Edgar Link unprocessable
kmph-ex101_274.htm Edgar Link pending
kmph-ex106_272.htm Edgar Link pending
kmph-ex107_273.htm Edgar Link pending
kmph-ex311_10.htm Edgar Link pending
kmph-ex312_7.htm Edgar Link pending
kmph-ex321_9.htm Edgar Link pending
kmph-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending